李进 主任医师，教授
硕士招生类型：无
硕士招生专业：无
博士招生类型：学术型；专业型
博士招生专业：肿瘤学
所在院系：附属东方医院
联系方式：lijin@csco.org.cn
课题组链接：
研究方向
主要任职
科研业绩

1. 恶性肿瘤（胃肠肿瘤）的内科治疗
2. 晚期肿瘤分子靶向治疗及免疫治疗
3. 新药I期临床研究
国家级学会任职：中国临床肿瘤学会（CSCO）理事长President of Chinese Society of Clinical Oncology(CSCO)
亚洲肿瘤学联盟（FACO)主席President of Federation of Asian Clinical Oncology (FACO)
亚洲肿瘤分子靶向治疗继续教育委员会（MTTC）常委Standing committee member of Medical Education Workshop on Molecular Targeted Therapy of Cancer (MTTC)
中国医师学会结直肠癌专业委员会副主任委员Vice chairman of Chinese medical doctor association colorectal cancer group
中国临床肿瘤学会药物安全专家委员会主任委员Chairman of Anti-cancer drug Safety Management Committee (ASMC)
上海市抗癌协会胃肠肿瘤专业委员会副主任委员Vice chairman of Shanghai Anti-cancer Association GI group
学术杂志编委：《Cancer Science》， 副主编Associate editor of Cancer Science
《Journal of Colorectal Cancer》中文版 ， 副主编Associate editor of Journal of Colorectal Cancer(Chinese version)
《中华肿瘤杂志》 编委Editor of Chinese Journal of Oncology
《癌症》 责任编委Editor of Cancer
《中国癌症杂志》 编委Editor of China Oncology
《临床肿瘤学杂志》 副主编Associate editor of Chinese Clinical Oncology
《Journal of Colorectal Cancer》中文版 副主编Associate editor of Journal of Colorectal Cancer (Chinese version)
《Journal of Hematology and Oncology》 编委Editor of Journal of Hematology and Oncology
《Clinical Cancer Drugs》 编委Editor of Clinical Cancer Drugs
近三年所有科研项目：1.科技部非传染性疾病防控研究（2017YFC**），胃癌靶向治疗新技术研究-靶向药物治疗胃癌的早期临床研究及多中心大样本临床研究；项目来源：中华人民共和国科技部；起止年月：2017.07-2020.12；资助金额：770万；
2017.07-2020.12 Title: targeted treatment for gastric cancer: early clinical trial and multi-center clinical trial
Grant NO.: 2017YFC** (￥7,700,000)
Major goal: to find new effective target for gastric cancer treament and investigate new drug for gastric cancer.
2.复发转移大肠癌的治疗新策略（2016ZX-07-003）；项目来源：国家卫生计生委医药卫生科技发展研究中心；起止年月：2016.11-2018.12；资助金额：1000万；
2016.11-2018.12 Title: new strategy for metastatic colorectal cancer
Grant NO.: 2016ZX-07-003 (￥10,000,000)
Major goal: to find new strategies for mCRC, especially targeted therapy and immunotherapy.
3.基于外显子测序技术筛选胃癌复发转移新基因CDH4突变及其功能研究；项目来源：国家自然科学基金；起止年月：2018.01-2020.12；资助金额：55万；
2018.01-2020.12 Title: role of CDH4 mutation in grastric cancer recurrence based on whole exome sequence
Grant NO.: 2016ZX-07-003 (￥10,000,000)
Major goal: to investigate the role of CDH4 mutation in gastric cancer recurrence, and possible mechanism.
4.国际标准抗肿瘤新药临床试验平台建设（2012ZX09303-018-002）；项目来源：国家十二五重大攻关计划课题；起止年月：2012.01-2017.12；资助金额：1400万。
2012.01-2017.12 Title: establishment of international standardized new platform for anti-cancer drug clinical trial.
Grant NO.: 2012ZX09303-018-002 (￥14,000,000)
Major goal: to establish new platform for new drug clinical trial.
近三年获奖成果：1.2014年“胃癌发生发展的分子机制研究与临床治疗新策略的建立和应用《国家教育部科技进步》二等奖。（排名第1）
2014 Ministry of Education Prize for Progress in Science and Technology, second award (No. 1).
2.2016年结直肠癌个体化治疗策略创新与应用《国家科技进步奖》二等奖 (排名第3)
2016 National Prize for Progress in Science and Technology, second award (No. 3).
近三年发表论著(第一作者或通讯作者）：[1] Li J, Qin SK, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496.
[2] Li J, Xu R, Xu J, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. Cancer Sci. 2017 Oct;108(10):2045-2051.
[3] Zheng PP, Li J, Kros JM.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev. 2018 Jan;38(1):325-376.
[4] Liu x, Zhang X, Li J, et al. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. Int J Cancer. 2017 Nov 15;141(10):2093-2102.
[5] Lin F, Dai C, Ge X, Tang W, Lin Y, Wang Y, Li J. Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer. Biochem Biophys Res Commun. 2017 Jun 3;487(3):619-624.
[6] Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017 Jan 19;10(1):22.
[7] Cao J, Zhang J, Peng W, Chen Z, Fan S, Su W, Li K, Li J. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Aug;78(2):259-69.
[8] Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54.
[9] Wang C, Guo W, Zhou M, Zhu X, Ji D, Li W, Liu X, Tao Z, Zhang X, Zhang Y, Li J. The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. Clin Cancer Res. 2016 Apr 1;22(7):1603-10.
[10] Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):619-29.
[11] Chen Z, Guo W, Cao J, Lv F, Zhang W, Qiu L, Li W, Ji D, Zhang S, Xia Z, Wang J, Li J. Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cancer Chemother Pharmacol. 2015 Mar;75(3):547-57.